Search company, investor...

Brii BioSciences

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Brii BioSciences

Brii BioSciences (02137.HK) is a developer of new medicines exclusively for the Chinese market, committed to serving patients' needs and improving public health in China. The company aims to accelerate the development, commercialization, and delivery of breakthrough infectious disease medicines in China through partnerships, research and development, and the application of digital and data insight.

Headquarters Location

One City Center 110 Corcoran Street, Office 05-130

Durham, North Carolina, 27701,

United States

Missing: Brii BioSciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Brii BioSciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Brii BioSciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Brii BioSciences is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Brii BioSciences Patents

Brii BioSciences has filed 4 patents.

The 3 most popular patent topics include:

  • Animal virology
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics



HIV/AIDS, Virology, Hepatotoxins, Molecular biology, Animal virology


Application Date


Grant Date


Related Topics

HIV/AIDS, Virology, Hepatotoxins, Molecular biology, Animal virology



Latest Brii BioSciences News

Chinese-based firms say they have minimal exposure to SVB

Mar 14, 2023

Tuesday, 14 Mar 2023 Customers wait in line outside a branch of the Silicon Valley Bank in Wellesley, Massachusetts, U.S., March 13, 2023. REUTERS/Brian Snyder HONG KONG: Over a dozen Hong Kong-listed companies say they have little or no exposure to Silicon Valley Bank, the failed US lender that has roiled investors and markets globally. Startup-focussed SVB Financial Group, which did business as Silicon Valley Bank, collapsed last Friday in the largest bank failure since the 2008 financial crisis. US officials have stepped in to stem the financial fallout and said that all customers will have access to their deposits. Chinese companies are making efforts to reassure clients and investors as the collapse of the US bank could have a negative psychological impact on China’s markets since many tech start-ups, especially those with dollar funding, have opened US accounts at SVB. On Saturday, SVB’s Chinese joint venture with Shanghai Pudong Development Bank said it has a sound corporate structure and an independently operated balance sheet. Firms scrambled through Sunday and yesterday to release statements on the extent of their exposure or to distance themselves from the bank. A China-based drug developer, Beigene Ltd, said it has uninsured cash deposits held at the bank, representing 3.9% of its last reported total cash and cash equivalents. It also said it did not expect the developments to impact its operations. Mobile advertising platform Mobvista Inc said it has deposit accounts with the bank with a balance of US$430,000 (RM1.94mil) and that the accounts represent a minimal portion of cash and cash equivalents. Six Hong Kong-listed companies, mostly Chinese pharmaceutical firms, also disclosed cash deposits at Silicon Valley Bank over the weekend. Brii Biosciences Limited revealed it had the highest percentage of cash and bank balances at SVB, at less than 9%. It did not provide a monetary figure for the deposits. “Notwithstanding the closure of SVB, the existing cash and bank balances of the company continue to be sufficient to meet its working capital, capital expenditures and material cash requirements from known contractual obligations for the next three years,” Brii Biosciences said. Broncus Holding Corporation said it held US$11.8mil (RM53.3mil) at SVB, representing around 6.5% of its total cash. — Reuters Article type: free

Brii BioSciences Frequently Asked Questions (FAQ)

  • When was Brii BioSciences founded?

    Brii BioSciences was founded in 2018.

  • Where is Brii BioSciences's headquarters?

    Brii BioSciences's headquarters is located at One City Center, Durham.

  • What is Brii BioSciences's latest funding round?

    Brii BioSciences's latest funding round is IPO.

  • How much did Brii BioSciences raise?

    Brii BioSciences raised a total of $415M.

  • Who are the investors of Brii BioSciences?

    Investors of Brii BioSciences include GIC, Invesco, Lake Bleu Capital, Blue Pool Capital, 6 Dimensions Capital and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.